ArticleJournal of diabetes investigation2026
Diabetes attenuates weight reduction-mediated liver fibrosis regression in persons with morbid obesity.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWeight loss by laparoscopic sleeve gastrectomy (LSG) compared to medical weight loss (low-calorie diet: LCD) ameliorates diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to evaluate changes in liver pathology 1-year after LSG and their associations with metabolic factors in Japanese participants with severe obesity. MATERIALS AND
methodsWe recruited 27 Japanese participants with severe obesity (BMI > 35 kg/m
resultsLSG significantly reduced histological scores in hepatic steatosis, hepatocellular ballooning, lobular inflammation, and hepatic fibrosis, together with fasting plasma glucose, hemoglobin A1c, body weight, body mass index, and liver enzymes. Reduction in steatosis was associated with a reduction in glycemic parameters and γ-glutamyl transpeptidase. Reduction in lobular inflammation was associated with reductions in liver enzyme levels and hemoglobin A1c. Changes in hepatic fibrosis were not associated with metabolic or biochemical changes but were related to baseline fibrosis severity and the presence of diabetes. Unexpectedly, weight reduction significantly lowered platelet counts and elevated the fibrosis-4 index.
conclusionLSG improves liver histopathology of MASLD in Japanese participants with severe obesity. The comorbidity of diabetes was associated with attenuated improvement in liver fibrosis after LSG, suggesting that glycemic status and diabetes-related factors may be key modifiers of fibrosis reversibility in MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.